Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels. Clin Endocrinol (Oxf), 48 () . La presencia de macroprolactina sérica es un hecho relativamente frecuente que puede conducir a exploraciones costosas y tratamientos ineficaces. Manejo terapéutico de la hiperprolactinemia. Therapeutic management of hyperprolactinemia. Visits. J M. Cabezas Agrícolaa, J. Cabezas-Cerratoa.

Author: Tarisar Yozshutaur
Country: Malawi
Language: English (Spanish)
Genre: Sex
Published (Last): 15 November 2015
Pages: 144
PDF File Size: 8.35 Mb
ePub File Size: 4.99 Mb
ISBN: 797-5-16665-369-3
Downloads: 17266
Price: Free* [*Free Regsitration Required]
Uploader: Zulkikree

Endocr Rev, 1pp.

Thyroid functions and serum lipids in older women: J Endocrinol Invest, 26pp. Endocrinol Nutr, 51pp.

Rheum Dis Clin North Am, 16pp. Longterm follow-up of women with surgical treated prolactin-secreting pituitary tumors.

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two receding years. SRJ is a prestige metric based on the idea that not all citations are the same. Am J Med,pp. J Clin Endocrinol Metab, 87pp.

Hospital de la Santa Creu i Sant Pau. CiteScore measures average citations received per document published.


[Current diagnosis and treatment of hyperprolactinemia].

Ann Clin Biochem, 34pp. Fertil Steril, 48pp. Are you a health professional able to prescribe or dispense drugs? Clin Endocrinol Oxf56pp. Previous article Next article. Diabetes Care, 19pp. Surgical treatment of prolactin-secreting pituitary adenomas: Role of estrogens in the management of postmenopausal bone loss.

Am Fam Physician, 72pp. N Engl J Med,pp. Thyroid disease in progressive systemic sclerosis.

Hiperprolactinemia por macroprolactina y disfunción eréctil | Endocrinología y Nutrición

Print Send to a friend Export reference Mendeley Statistics. SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field.

Peptides, 23pp. Other structural causes of hyperprolactinemia include non-functioning pituitary adenomas and infiltrative disorders, which can interrupt the inhibitory, descending dopaminergic tone.

Epidemiology and natural history of systemic sclerosis. Med Int Mex, 22pp.

Hiperprolactinemia tumoral y obesidad | Endocrinología y Nutrición

Acta Endocrinol,pp. To improve our services and products, we use “cookies” own or third parties authorized to show advertising related to client preferences through the analyses of navigation customer behavior. You can change the settings or obtain more information by clicking here. The primary treatment of prolactinomas is pharmacological with dopamine agonists such as cabergoline. The osteoporosis in escleroderma is multifactorial ischemia, immobilization, intestinal malabsorption syndrome, steroids, menopause, hyperprolactinemia, among other.


Rheumatology, 38pp. The natural history of untreated hyperprolactinemia: January Pages The journal fully endorses the goals of updating knowledge and facilitating the acquisition of key developments in internal medicine applied to clinical practice.

Prevalence of subclinic thyroid disease in mexican systemic sclerosis patients. Hiperprolacrinemia tumors and hypogonadism in 22 men. April Pages Clin Exp Rheumatol, 19pp.

McGraw-Hill Interamericana; [en prensa]. Are you a health professional able to prescribe or dispense drugs? Neuropathic pain in Systemic Sclerosis patients: Increased body weight associated with prolactin secreting pituitary adenomas: Rev Mex Reumatol, 17pp. Hyperprolactinemia is a frequent neuroendocrinological condition that should be approached in an orderly and integral fashion, starting with a complete hiperprklactinemia history.

Prolactin and thyroid hormones in patients with systemic sclerosis: